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Abstract
Background: Thyroid hormones are critical for growth and brain development during the newborn period and
infancy. Because of delayed maturation of the hypothalamic-pituitary-thyroid axis in preterm infants, thyroid
dysfunction is common, and thyroid stimulating hormone (TSH) elevation is often delayed in preterm infants. The
objective of this study was to determine the incidence of thyroid dysfunction requiring levothyroxine treatment
and to identify its risk factors in preterm infants.
Methods: A retrospective cohort study was performed on preterm infants who were born before 32 gestational
weeks and admitted to a single tertiary academic center for more than 8 weeks between January 2008 and
December 2014. In these infants, serial thyroid function tests (TFTs) measuring serum TSH and free thyroxine (fT4)
were routinely performed at 1, 3, and 6 weeks of postnatal age.
Results: Of the 220 preterm infants enrolled, 180 infants underwent TFTs at 1, 3, and 6 weeks of postnatal age and
were included in the study. Of the 180 infants, 35 infants (19.4%) were started on levothyroxine treatment based on
the results of serial TFTs. Among the 35 infants who were treated with levothyroxine, 16 infants (45.7%) had normal
results on the initial TFT. Three of these 16 infants continued to have normal results on the second TFT. Thyroid
dysfunction requiring levothyroxine treatment was significantly associated with maternal pregnancy-induced
hypertension (adjusted odds ratio 2.64, 95% confidence interval 1.02–6.81).
Conclusions: Thyroid dysfunction requiring levothyroxine treatment occurred in nearly one-fifth of preterm infants
born before 32 gestational weeks. Nearly half of the preterm infants who were treated with levothyroxine had
normal TSH and fT4 levels at 1 week of postnatal age. The findings of the present study suggest that serial TFTs is
important to find preterm infants who require levothyroxine treatment.
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Background
Thyroid hormones play a critical role in the maturation of
the brain, and hypothyroidism causes neurodevelopmental
impairment if not treated properly [1]. Hypothyroidism is
common in preterm infants due to immaturity of the
hypothalamic-pituitary-thyroid axis, impaired synthesis
and metabolism of thyroid hormones, increased demand
for thyroid hormone due to nonthyroidal illness, and drug
administration [2].
Preterm infants may develop hypothyroidism even
when initial thyroid function tests within the first few
days of life show normal thyroid-stimulating hormone
(TSH) and free thyroxine (fT4) levels. Hypothyroxinemia
of prematurity is characterized by low levels of circulat-
ing thyroid hormones despite normal TSH levels [3].
Hypothyroxinemia of prematurity is common in preterm
infants, occurring in 20% of preterm infants born before
34 gestational weeks and in 29% of very low birth weight
(VLBW) infants born before 32 gestational weeks [4, 5],
due to blunted postnatal TSH surges and low serum
thyroxine (T4) and tri-iodothyronine (T3) levels during
the first few weeks of life [2]. Additionally, preterm in-
fants have a higher risk of delayed TSH elevation [6].
Delayed TSH elevation is defined as elevated TSH at the
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second neonatal screening test despite a normal TSH
level at the initial screening test regardless of fT4 levels
[7]. The incidence of delayed TSH elevation is estimated
to be up to 12% in preterm infants [8, 9], which is sig-
nificantly higher than that in term infants [10].
Thus, preterm infants are subject to hypothyroxinemia
of prematurity and/or delayed TSH elevation [6, 11].
However, whether and how to screen for these thyroid
dysfunctions in preterm infants remain controversial. Cur-
rently, no universal guidelines are available regarding the
indication and timing for screening and the diagnosis and
treatment of thyroid dysfunction in preterm infants.
Furthermore, whether untreated thyroid dysfunction in
preterm infants affects neurodevelopmental outcomes re-
mains unknown.
We aimed to evaluate the incidence of thyroid dys-
function requiring levothyroxine treatment and to iden-
tify the associated risk factors in preterm infants born
before 32 gestational weeks.
Methods
Study subjects
This study enrolled all preterm infants who were born
before 32 gestational weeks and admitted to the neonatal
intensive care unit (NICU) of Seoul National University
Bundang Hospital for more than 8 weeks between
January 1, 2008, and December 31, 2014. Since January
2008, serial thyroid function tests (TFTs) measuring
both serum TSH and fT4 levels have been performed
routinely at 1, 3, and 6 weeks of postnatal age for pre-
term infants born before 32 gestational weeks and
admitted to the NICU. Serum TSH and fT4 levels were
measured by in-house radioimmunoassays. To assess
changes in serial TFTs over time, we included all infants
who underwent complete screening procedure according
to the institutional protocol. Even if the results of the
initial TFT (from 5 days to 9 days of life) were normal,
TFTs were repeated at 3 weeks (from 14 days to 28 days
of life) and 6 weeks (from 29 days to 56 days of life) ac-
cording to our institutional protocol. If the results of the
TFT were abnormal (TSH > 6 μU/mL and/or fT4 < 0.8
ng/dL), the TFT was repeated after one or 2 weeks at
the discretion of the in-house pediatric endocrinologists
(HR Chung and MJ Kang). Levothyroxine treatment was
started in infants with serum TSH levels ≥20 μU/mL,
regardless of the fT4 level, on any of the serial TFTs or
in infants with persistently elevated serum TSH levels
(between 10 and 19.9 μU/mL) and persistently low fT4
levels (< 0.8 ng/dL). Levothyroxine treatment was started
with an initial dose of 10 to 15 μg/kg depending on the
severity of thyroid dysfunction. Follow-up TFTs were
performed every 2–4 weeks after starting levothyroxine
treatment. Once started, levothyroxine treatment was
continued until 2–3 years of age.
Data collection
Clinical data were retrospectively collected from the
electronic medical records. Maternal and perinatal data
included gestational diabetes mellitus, pregnancy-induced
hypertension (PIH), maternal thyroid disease, premature
rupture of membranes (PROM), use of antenatal cortico-
steroids, gestational age, birth weight, sex, multiple
gestations, delivery mode, and Apgar scores at 1 and 5
min. Neonatal morbidity data included respiratory distress
syndrome (RDS), patent ductus arteriosus (PDA),
necrotizing enterocolitis (NEC), culture-proven sepsis,
intraventricular hemorrhage (IVH), cystic periventricular
leukomalacia (PVL), retinopathy of prematurity (ROP),
and bronchopulmonary dysplasia (BPD). PDA was
diagnosed with echocardiography, and symptomatic PDA
was defined as hemodynamically significant PDA requir-
ing medical or surgical closure. BPD was defined as the
need for supplemental oxygen or assisted ventilation,
including nasal continuous positive airway pressure at 36
weeks postmenstrual age (PMA) according to NIH criteria
[12]. Early-onset sepsis (EOS) was defined as blood
culture-proven bacterial sepsis that occurred before 7 days
of life, while late-onset sepsis (LOS) occurred after 7 days
of life. Other morbidities included IVH ≥ grade III [13],
NEC with modified Bell stage ≥ II [14], and ROP at a high
stage requiring laser therapy [15].
Statistical analysis
Comparisons of continuous variables between the
groups were performed with a Student t-test for nor-
mally distributed variables and a Mann-Whitney U test
for variables with nonnormal distributions. Categorical
variables were compared with a Pearson chi-square test.
Multiple logistic regression analyses were performed to
identify risk factors associated with thyroid dysfunction
requiring levothyroxine treatment. Statistical analyses
were performed using the IBM SPSS Statistics software
package version 24.0 (IBM, Armonk, NY). P-values <
0.05 were considered significant.
Ethical statement
The Seoul National University Bundang Hospital
Institutional Review Board (IRB) approved the collec-
tion and use of the clinical information of the
patients for research purposes before the investigation
was started and waived the requirement for informed
consent (IRB No. B1806–486-101).
Results
Study subjects
From January 2008 to December 2014, 220 preterm
infants who were born before 32 gestational weeks and
admitted to the NICU for more than 8 weeks were en-
rolled. Of these 220 infants, 40 infants for whom serial
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TFTs at three time points (1, 3, and 6 weeks of postnatal
age) were not completely performed were excluded.
Ultimately, 180 infants who underwent complete screen-
ing procedure were included in the analyses. The mean
gestational age of the study subjects was 27+ 5 weeks
(range: 23+ 1–31+ 6 weeks), and their mean birth weight
was 1008 g (range: 420–2275 g). The male to female
ratio was 1.1.
Serial thyroid function tests and levothyroxine treatment
The mean postnatal ages at the initial, second and third
TFTs were 6.9 ± 1.1 (range: 5–9), 22.2 ± 3.7 (range: 15–
28), and 42.1 ± 6.6 (range: 29–56) days, respectively. Of
the 180 infants, 52 infants (28.9%) showed abnormal re-
sults on the initial TFT, and 128 infants (71.1%) showed
normal results on the initial TFT. The outcomes of 52
infants with abnormal initial TFT results and 128 infants
with normal initial TFT results are presented in Fig. 1.
Three infants were started on levothyroxine treatment
after exhibiting abnormal results on the initial TFT.
Another 14 infants were started on levothyroxine
treatment after exhibiting abnormal results on the sec-
ond TFT, and another 11 infants were started on
levothyroxine treatment after exhibiting abnormal re-
sults on the third TFT. Finally, 7 infants were started on
levothyroxine treatment after exhibiting abnormal re-
sults on subsequent TFTs. Consequently, 35 infants
(19.4%) were started on levothyroxine treatment during
the NICU admission. Of the 35 infants who were started
on levothyroxine treatment during the NICU admission,
16 (45.7%) showed normal results on the initial TFT. Of
the 16 infants who showed normal results on the initial
TFT, 3 (18.8%) continued to show normal results on the
second TFT. Of the 3 infants who showed normal
results on both the initial and second TFTs, one contin-
ued to show normal results on the third TFT. The re-
sults of serial TFTs of the 35 infants who were started
on levothyroxine treatment during the NICU admission
are presented in Fig. 2. Among the 35 infants who were
treated with levothyroxine, levothyroxine treatment was
Fig. 1 Outcomes of 128 infants with normal initial thyroid function test results and 52 infants with abnormal initial thyroid function test results.
TFT, thyroid function test; Tx, levothyroxine treatment; subseq., subsequent
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started in 13 infants with serum TSH ≥20 μU/mL and
normal fT4, 14 infants with serum TSH ≥20 μU/mL and
low fT4, and 8 infants with serum TSH levels between
10 and 19.9 μU/mL and low fT4.
The mean serum TSH levels of the infants who were
determined not to require levothyroxine treatment ac-
cording to the initial, second, and third TFTs were
4.61 ± 3.52 μU/mL (n = 177), 6.54 ± 4.07 μU/mL (n =
163), and 4.46 ± 2.74 μU/mL (n = 152), respectively. The
mean serum fT4 levels of the infants who were deter-
mined not to require levothyroxine treatment according
to the initial, second, and third TFTs were 1.29 ± 0.34
ng/dL (n = 177), 1.32 ± 0.31 ng/dL (n = 163), and 1.34 ±
0.26 ng/dL (n = 152), respectively. The mean serum TSH
levels of the infants who were determined to require
levothyroxine treatment according to the initial, second,
and third TFTs were 29.00 ± 35.18 μU/mL (n = 3),
80.17 ± 107.49 μU/mL (n = 14), and 60.49 ± 71.06 μU/mL
(n = 11), respectively. The mean serum fT4 levels of the
infants who were determined to require levothyroxine
treatment according to the initial, second, and third
TFTs were 0.69 ± 0.04 ng/dL (n = 3), 0.81 ± 0.40 ng/dL
(n = 14), and 1.01 ± 0.46 ng/dL (n = 11), respectively.
Baseline characteristics of the levothyroxine treatment
and nontreatment groups
Thirty-five infants who were started on levothyroxine
treatment were compared with 145 infants who were
not given levothyroxine treatment. No significant differ-
ence in the baseline characteristics was found between
the two groups, except that maternal PIH (40.0%
vs.16.6%, p = 0.002) and cesarean section (82.9% vs.
65.5%, p = 0.047) were significantly more common in the
levothyroxine treatment group than in the levothyroxine
non-treatment group. After adjustment for covariates
including gestational age and birth weight percentile as
categorical variables (23–25 weeks, 26–28 weeks, 29–31
weeks for gestational age, < 33%, 33–67, > 67% for birth
weight percentile), cesarean section, and maternal PIH,
only maternal PIH was significantly associated with
levothyroxine treatment in multivariable logistic
Fig. 2 Results of serial thyroid function tests of the 35 infants who were started on levothyroxine treatment during their neonatal intensive care
unit admission. TFT, thyroid function test; Tx, levothyroxine treatment. Open boxes indicate infants who were not on levothyroxine treatment at
the time of their thyroid function test. Solid boxes indicate infants who were on levothyroxine treatment at the time of their thyroid function test
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regression analysis (Adjusted odds ratio (OR) 2.64, 95%
confidence interval (CI) 1.02–6.81; p = 0.045) (Table 1).
Neonatal comorbidities in the levothyroxine treatment
and nontreatment groups
The incidences of IVH (≥ grade III), symptomatic PDA,
NEC (≥ stage II), late-onset neonatal sepsis, BPD, and
ROP requiring laser therapy were not significantly differ-
ent between the levothyroxine treatment group and the
levothyroxine nontreatment group. However, cystic PVL
was significantly more common in the levothyroxine
treatment group than in the levothyroxine nontreatment
group (22.9% vs. 9.7%, p = 0.044). After adjustment for
covariates including gestational age and birth weight
percentile as categorical variables (23–25 weeks, 26–28
weeks, 29–31 weeks for gestational age; < 33%, 33–67, >
67% for birth weight percentile), cesarean section, mater-
nal PIH, and cystic PVL, cystic PVL was consistently
associated with levothyroxine treatment in multivariable
logistic regression analysis (adjusted OR 3.77, 95% CI
1.30–10.96; p = 0.015) (Table 2).
Follow-up of the infants with thyroid dysfunction
requiring levothyroxine replacement
Of the 35 infants who were started on levothyroxine
treatment during the NICU admission, two infants who
were transferred to other hospitals were not followed up,
and 33 infants underwent regular follow-up examina-
tions at the outpatient clinic in our center after dis-
charge until they were 3 years old. All 33 infants were
able to discontinue levothyroxine treatment between 2
and 3 years of age.
Discussion
In this study, we found that repeated assessment of
serum TSH and fT4 levels in preterm infants is neces-
sary to avoid missing thyroid dysfunction requiring
levothyroxine treatment. Among the 35 infants who
were started on levothyroxine treatment during the
NICU admission, 16 (45.7%) had normal results on the
initial TFT. Furthermore, 3 of these 16 infants continued
to have normal results on the second TFT.
Due to lack of maternal supply of thyroid hormone dur-
ing the third trimester, preterm infants are vulnerable to
develop transient hypothyroxinemia [3]. Additionally, the
feedback loop of the hypothalamic-pituitary-thyroid axis is
not fully developed, which results in delayed TSH eleva-
tion in response to low thyroid hormone levels in preterm
infants [16]. Although the thyroid function of preterm in-
fants reaches the same level as that of full-term infants at
4–6 weeks of postnatal age, some may have greater and
more persistent delayed TSH elevation or hypothyroxine-
mia of prematurity, which may require levothyroxine
treatment [17]. In the present study, the overall incidence
of thyroid dysfunction requiring levothyroxine treatment
was 19.4% in preterm infants who were born before 32
gestational weeks and hospitalized more than 8 weeks. In
recent studies, the incidence rates of thyroid dysfunction
requiring levothyroxine treatment were 12.2% in VLBW
infants and 9.1% in preterm infants born before 30






Maternal age (years) 32.6 ± 3.3 32.1 ± 3.6 0.408 –
Gestational age (weeks+days) 27+ 5 ± 2+ 0 27+ 6 ± 2+ 0 0.931 –
Birth weight (g) 1026 ± 329 935 ± 266 0.133 –
Male (%) 79 (54.5) 17 (48.6) 0.529 –
Caesarean section (%) 95 (65.5) 29 (82.9) 0.047 –
Multiple gestation (%) 46 (31.7) 6 (17.1) 0.088 –
Antenatal corticosteroids (%) 128 (88.3) 32 (91.4) 0.594 –
Premature rupture of membrane (%) 70 (48.3) 11 (31.4) 0.072 –
Pregnancy-induced hypertension (%) 24 (16.6) 14 (40.0) 0.002 0.045
Gestational diabetes (%) 9 (6.2) 0 (0.0) 0.130 –
Maternal thyroid disease (%) 1 (0.7) 0 (0.0) 1.000 –
1 min Apgar score 4.0 ± 1.9 3.8 ± 1.9 0.586 –
5 min Apgar score 6.1 ± 1.7 5.7 ± 1.7 0.274 –
Respiratory distress syndrome (%) 112 (77.2) 26 (74.3) 0.711 –
Early-onset sepsis (%) 1 (0.7) 2 (5.7) 0.097 –
Values are presented as the means±SDs or numbers (%)
*Adjusted for variables including gestational age and birth weight percentile used as categorical variables (23–25 weeks, 26–28 weeks, 29–31 weeks for gestational
age; < 33%, 33–67, > 67% for birth weight percentile), cesarean section and maternal pregnancy-induced hypertension
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gestational weeks [18, 19]. Compared to these recent stud-
ies, our study found a higher incidence of thyroid dysfunc-
tion requiring levothyroxine treatment. Because only
preterm infants who were hospitalized for more than 8
weeks were enrolled in our study, the study population
might have consisted of more immature and sicker
preterm infants. However, considering the differences in
study populations, the incidence of thyroid dysfunction
requiring levothyroxine treatment is notable. Therefore,
some researchers have suggested that TFTs should be
repeated at regular intervals to identify thyroid dysfunc-
tion associated with delayed TSH elevation or hypothyrox-
inemia of prematurity in preterm infants. Different
approaches have been suggested to avoid missing thyroid
dysfunction requiring levothyroxine treatment. Some
guidelines recommend routine screening tests for thyroid
function at 2 and 6 weeks of age in all VLBW and LBW
infants in the NICU [20]. In some regions of the United
States, serum fT4 and TSH levels are measured at 2, 6 and
10 weeks of postnatal age in all VLBW infants [21]. The
European Society for Pediatric Endocrinology guidelines
recommend that a repeat specimen should be collected at
2 weeks of postnatal age or 2 weeks after the first screen-
ing tests for thyroid function for preterm infants or VLBW
infants [22]. In our center, both serum fT4 and TSH levels
are measured at 1, 3 and 6 weeks of postnatal age for pre-
term infants born before 32 gestational weeks, as reported
previously [8]. In the present study, the rates of abnormal
results on the initial, second, and third TFT were 28.9%
(52/180), 57.1% (101/177), and 29.4% (48/163), respect-
ively. Of the 128 infants who showed normal results on
the initial TFT, 65 (50.8%) showed abnormal results on
the second TFT. Furthermore, 9 (14.3%) of the 63 infants
who had normal results consecutively on the initial and
second TFTs showed abnormal results on the third TFT.
These results suggest that a single or two TFTs may be
insufficient to identify thyroid dysfunction in preterm
infants. In our study, only one infant was further started
on levothyroxine treatment after showing normal results
on all three serial TFTs. This infant had severe
encephalomalacia. Subsequent TFTs were performed on
this infant after 8 weeks of age because of clinical suspi-
cion of thyroid dysfunction.
Thyroid dysfunction is common in more immature
preterm infants. The incidence of hypothyroxinemia of
prematurity is inversely correlated with gestational age
[23]. Van Wassenaer et al. [2] found that smaller and
more immature preterm infants have significantly lower
fT4 levels than more mature preterm infants or term in-
fants. Delayed TSH elevation has also been associated
with low birth weight [18, 19]. In contrast, thyroid dys-
function requiring levothyroxine treatment was not asso-
ciated with gestational age or birth weight in this study.
A few studies have demonstrated that delayed TSH ele-
vation is not associated with gestational age or birth
weight [24]. These inconsistent results among studies
may be explained by differences in sample sizes, refer-
ence ranges for TFTs or definitions of hypothyroxinemia
of prematurity and delayed TSH elevation between the
studies.
Infants who required levothyroxine treatment were
delivered by cesarean section more frequently in the
present study. Several studies demonstrated that the as-
sociation between cesarean section and delayed TSH ele-
vation [7, 25, 26]. However, the association of cesarean
section with the levothyroxine treatment might be due
to a confounding effect resulting from an association
between maternal PIH and cesarean section. Because
maternal PIH was a common indication for preterm
cesarean section, cesarean section was significantly asso-
ciated with maternal PIH (p = 0.007).
After adjustment for covariates, only maternal PIH
was significantly associated with thyroid dysfunction re-
quiring levothyroxine treatment on multivariate analysis
in this study. Similar to our results, several studies re-
ported that higher TSH levels or lower fT4 levels were
observed in preterm infants born to mothers with PIH
[27–29]. Because maternal PIH can lead to placental in-
sufficiency, it may decrease placental passage of T4 from
the mother to fetus, and therefore, hypothyroxinemia or






Intraventricular hemorrhage (≥grade III) (%) 7 (4.8) 5 (14.3) 0.059 –
Symptomatic patent ductus arteriosus (%) 81 (55.9) 24 (68.6) 0.187 –
Necrotizing enterocolitis (≥stage II) (%) 13 (9.0) 3 (8.6) 1.000 –
Late-onset sepsis (%) 12 (8.3) 6 (17.1) 0.124 –
Bronchopulmonary dysplasia (%) 73 (50.3) 19 (54.3) 0.710 –
LASER therapy for retinopathy of prematurity (%) 39 (26.9) 11 (31.4) 0.675 –
Periventricular leukomalacia (%) 14 (9.7) 8 (22.9) 0.044 0.015
Values are presented as numbers (%)
*Adjusted for variables including gestational age and birth weight percentile used as categorical variables (23–25 weeks, 26–28 weeks, 29–31 weeks for gestational
age; < 33%, 33–67, > 67% for birth weight percentile), cesarean section, maternal pregnancy-induced hypertension and periventricular leukomalacia
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delayed TSH elevation after preterm birth might be
aggravated.
Among the comorbidities examined, only cystic PVL was
significantly associated with thyroid dysfunction requiring
levothyroxine treatment. Thyroid hormones play an im-
portant role in the development of the central nervous sys-
tem during the fetal and early neonatal periods [30]. In
particular, thyroid hormones are very important for the de-
velopment of cerebral circumvolutions and white matter
and myelination [31]. Hypothyroxinemia of prematurity has
been associated with PVL [32, 33]. In a retrospective multi-
center study of VLBW infants, cerebral white matter injury
was twice as common in infants exposed to low total T4
levels compared to infants exposed to higher total T4 levels
[32]. The causal relationship between thyroid dysfunction
requiring levothyroxine and cystic PVL could not be deter-
mined in this study. However, some speculations can be
made on this association. First, exposure to hypothyroxine-
mia before initiation of levothyroxine treatment might have
contributed to the development of white matter injury. Sec-
ond, thyroid dysfunction requiring levothyroxine treatment
might have shared risk factors or underlying conditions
with cystic PVL.
We also found that all preterm infants with thyroid
dysfunction requiring levothyroxine treatment had
transient hypothyroidism, suggesting that thyroid
dysfunction in preterm infants may often be transient.
Recent studies have advocated that the course of
hypothyroidism is transient in many preterm infants and
that discontinuing levothyroxine supplementation is pos-
sible before 3 years of age [34, 35]. Preterm birth and asso-
ciated clinical conditions can result in temporary thyroid
dysfunction that can persist for several days to months
[36]. However, long term neurodevelopmental outcomes
of transient hypothyroidism should be evaluated.
Our study has some limitations. The retrospective
design involving a single center and a lack of long-term
neurodevelopmental outcome data are weak points of
the present study. Moreover, preterm infants who were
born before 32 gestational weeks and admitted to the
NICU for more than 8 weeks were included in the study
population. These infants would have been more imma-
ture and sicker and, thus, would have been more likely
to exhibit higher incidence of severe ROP, PVL, and thy-
roid dysfunction requiring levothyroxine treatment. Fur-
ther studies are required to determine the long-term
neurodevelopmental consequences of thyroid dysfunc-
tion requiring levothyroxine treatment and to identify
optimal thyroid function screening methods for preterm
infants.
Conclusion
Thyroid dysfunction requiring levothyroxine treatment
occurred in nearly one-fifth of preterm infants born
before 32 gestational weeks. Nearly half of the preterm
infants who were treated with levothyroxine had normal
TSH and fT4 levels at 1 week of postnatal age. The find-
ings of the present study suggest the importance of serial
TFTs in preterm infants to identify patients who require
thyroid replacement therapy.
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